Navigation Links
Interim Results Reported for Phase I Open-Label Clinical Trial for the Treatment of PTSD and MDD Using External Trigeminal Nerve Stimulation (eTNS™) - The USB Port to the Brain™
Date:5/30/2012

LOS ANGELES, May 30, 2012 /PRNewswire/ -- Today, at the 52nd annual New Clinical Drug Evaluation Unit (NCDEU) Conference in Arizona, Ian Cook, M.D., Professor of Psychiatry at the University of California, Los Angeles (UCLA) and a Senior Medical Advisor to NeuroSigma, Inc., presented the results from the first 6-subject cohort of a 10-subject Phase I open-label clinical trial studying the effects of external trigeminal nerve stimulation (eTNS™) on Post-Traumatic Stress Disorder (PTSD) and depressive symptoms in Major Depressive Disorder (MDD) as an adjunct to pharmacotherapy.  The trial is being conducted at UCLA and is funded by NeuroSigma.  Mean decreases in PTSD measures of 36% and depression measures of over 50% were reported.

The study was conducted over an 8-week period and followed similarly designed eTNS trials conducted at UCLA, in which promising results were generated in treating both major depression and epilepsy.  Subjects had a mean age of 54 with a median of 28 years since traumatic exposure and suffered from both PTSD and MDD.  Current episodes were required to be of at least four months in duration, with non-response to at least one antidepressant.  In this outpatient trial, subjects placed stimulating eTNS electrodes on their foreheads for approximately eight hours each night while asleep, and the severity of PTSD and depression symptoms was measured every two weeks using standard recognized rating scales. 

"These findings are very encouraging," said Dr. Cook.  "The combination of depression and an anxiety disorder, like PTSD, is usually difficult to treat effectively.  The participants in the study told us that eTNS was easy to use at home and led, in some instances, to the best mental health they had experienced in years.  We expect these results, along with results from the remaining subjects in this Phase I trial, to form the basis for an upcoming Phase II clinical trial
'/>"/>

SOURCE NeuroSigma
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Interim results of VITOBA™ (VImpaT® added to One Baseline AED) Study Presented at the 64th Annual Meeting of the American Academy of Neurology
2. Codexis Appoints Interim Chief Executive Officer
3. Savient Pharmaceuticals Appoints David Y. Norton Interim Chief Executive Officer
4. Quark Pharmaceuticals Reports Favorable Interim Results from Phase I Clinical Study of QPI-1007 in Patients with Non-arteritic Anterior Ischemic Optic Neuropathy (NAION)
5. Breast Cancer Vaccine Reduces Cancer Recurrence in Women: Interim Results From Phase 2 Clinical Trial Trend Toward AE37 Vaccine Benefit; Results Presented at SABCS
6. Golden Meditech FY2011-12 Interim Results
7. Positive Interim Results from Interferon-Free Phase 2b SOUND-C2 Study with Boehringer Ingelheims Two Investigational HCV Direct Acting Antivirals Presented at AASLD
8. Interim Data Announced for BIBF 1120 as Compared to bevacizumab in Combination Chemotherapy in Metastatic Colorectal Cancer
9. Dr. Eva Feldman, Principal Investigator, Presents Interim Data on Neuralstem ALS Trial
10. Niiki Pharma Announces Positive Interim Data from Ongoing Clinical Trial of Novel Anti-Cancer Agent NKP-1339
11. Landauer Elects Board Member Michael T. Leatherman as Interim Chief Financial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... Aug. 21, 2014  ACI Clinical ( www.aciclinical.com ... Data Monitoring Committees. Using this solution, ... over industry standard costs and receive the same ... in committee services. Leveraging a decade ... contracting, charter development, statistical programming and meeting facilitation), ...
(Date:8/21/2014)... PARK, N.J. , Aug. 21, 2014 /PRNewswire/ ... pharmacy group purchasing organization (GPO), is pleased to ... to collaborate on a host of innovative specialty ... help Aurora deliver enhanced therapy management services to ... Management (OTM) system. Aurora will use ...
(Date:8/21/2014)... N.Y. , Aug. 21, 2014  The board ... ), a leading provider of clinical trial imaging solutions, ... been named chief financial officer, effective immediately.  Mr. Groff ... since August 2013.  He joined VirtualScopics in January 2006 ... in February 2013. "When the board of ...
Breaking Medicine Technology:ACI Clinical: Innovation and Savings in Data Safety Monitoring Committees 2Aurora Health Care Partners with Armada Health Care to Deliver Added Pharmacy Capabilities to Specialty Patients 2Aurora Health Care Partners with Armada Health Care to Deliver Added Pharmacy Capabilities to Specialty Patients 3VirtualScopics, Inc. Names James Groff Chief Financial Officer 2VirtualScopics, Inc. Names James Groff Chief Financial Officer 3VirtualScopics, Inc. Names James Groff Chief Financial Officer 4
... NOVATO, Calif., Aug. 30 BioMarin Pharmaceutical Inc. (Nasdaq: ... received orphan drug designation from the U.S. Food and ... insulin-like growth factor 2 and alpha glucosidase (IGF2-GAA) in ... new drug application (IND) for BMN-701 has been submitted, ...
... ROCKVILLE, Md., Aug. 30 Sequella, Inc., a ... for life-threatening infectious diseases, announced today the restatement ... University of Maryland, Baltimore (UMB), concerning certain technology ... technology patent (U.S. 6,663,846), jointly owned by Sequella ...
Cached Medicine Technology:BioMarin Receives Orphan Drug Designation from the FDA for BMN-701 for the Treatment of Pompe Disease 2BioMarin Receives Orphan Drug Designation from the FDA for BMN-701 for the Treatment of Pompe Disease 3Sequella and University of Maryland Restate Exclusive License for Jointly Owned Event Marker System Technology 2Sequella and University of Maryland Restate Exclusive License for Jointly Owned Event Marker System Technology 3
(Date:8/21/2014)... a woman is to focus on her body in ... than viewing her as a complete human being with ... a problem in the media, how does it affect ... of Women Quarterly , a SAGE journal, finds that ... to higher incidents of sexual pressure and coercion., Researchers ...
(Date:8/21/2014)... Researchers in the United Kingdom have demonstrated that advanced ... diagnose a number of rare diseases marked by childhood ... today in Ophthalmology , the journal of the ... doctors were able to tailor care specifically to a ... and money spent on diagnosis and enabling earlier treatment ...
(Date:8/21/2014)... Xarelto lawsuit ( http://www.xareltolawsuitcenter.com/ ) filings ... uncontrollable internal bleeding and other serious injuries continue to ... to court documents, a wrongful death lawsuit was filed ... of New York by the family of a Tennessee ... was allegedly caused by Xarelto. Among other thing, the ...
(Date:8/21/2014)... The report "Industrial Flue Gas ... System (FGD, DeNOx, Particulate Control, Mercury Control) by ... & Others) - Global Trends & Forecasts to ... gas treatment systems & services market with analysis ... terms of value. The industrial flue gas treatment ...
(Date:8/21/2014)... (PRWEB) August 21, 2014 According to ... “Home Audio Equipment (Product Types - Home Theatre in-a-box, ... Market - Global Industry Analysis, Size, Share, Growth, Trends ... at USD 15.94 billion in 2012 and is expected ... a CAGR of 3.7% from 2013 to 2019. Europe ...
Breaking Medicine News(10 mins):Health News:Objectification in romantic relationships related to sexual pressure and coercion 2Health News:New DNA test for diagnosing diseases linked to childhood blindness 2Health News:Xarelto Lawsuits Mount With New Filing in New York Federal Court, Bernstein Liebhard LLP Reports 2Health News:Xarelto Lawsuits Mount With New Filing in New York Federal Court, Bernstein Liebhard LLP Reports 3Health News:Xarelto Lawsuits Mount With New Filing in New York Federal Court, Bernstein Liebhard LLP Reports 4Health News:Industrial Flue Gas Treatment Systems Market Estimated to Worth $59, 546.7 Million by 2019 – Report by MarketsandMarkets 2Health News:Industrial Flue Gas Treatment Systems Market Estimated to Worth $59, 546.7 Million by 2019 – Report by MarketsandMarkets 3Health News:Industrial Flue Gas Treatment Systems Market Estimated to Worth $59, 546.7 Million by 2019 – Report by MarketsandMarkets 4Health News:Home Audio Equipment Market Expected to Reach USD 20.68 Billion in 2019 2Health News:Home Audio Equipment Market Expected to Reach USD 20.68 Billion in 2019 3
... carcinoma but relatively few patients are cured. Combined neoadjuvant ... survival but there is concern about treatment morbidity and ... research team from China used a prospective study, based ... postoperative CRT to surgery alone in patients with resectable ...
... idiopathic skeletal hyperostosis (DISH) is a common but ... people. All papers related to DISH demonstrate a ... advancing age. Various local structural lesions such as ... cervical osteophytes may lead to mechanical esophageal dysphagia. ...
... beyond the liver, researchers say , FRIDAY, April 9 ... virus are at much higher risk of developing kidney ... than 67,000 patients enrolled in the Henry Ford Health ... with hepatitis C developed kidney cancer. That,s double the ...
... , FRIDAY, April 9 (HealthDay News) -- Nearly half ... school-aged children are due to overuse -- and many ... the message from the just-launched Stop Sports Injuries campaign, ... and elite athletes, including professional golf legend Jack Nicklaus; ...
... ... New York Clinical Information Exchange, based in Buffalo, NY, has selected the Anakam to ... ... 9, 2010 -- Anakam announced today that HEALTHeLINK the Western New York Clinical Information ...
... Singapore ... procedures. With success rates topping 90 percent across a range of complex surgeries, the country ... ... National Eye Centre (SNEC) is the first and only specialist eye centre outside of ...
Cached Medicine News:Health News:Perioperative chemoradiotherapy in esophageal squamous cell carcinoma 2Health News:More Kids Falling Prey to Sports Overuse Injuries 2Health News:More Kids Falling Prey to Sports Overuse Injuries 3Health News:HEALTHeLINK Selects ANAKAM To Provide Cloud Based Community Wide Two Factor Authentication 2Health News:HEALTHeLINK Selects ANAKAM To Provide Cloud Based Community Wide Two Factor Authentication 3Health News:HEALTHeLINK Selects ANAKAM To Provide Cloud Based Community Wide Two Factor Authentication 4Health News:Singapore Performs Cutting-edge Eye Surgeries 2Health News:Singapore Performs Cutting-edge Eye Surgeries 3Health News:Singapore Performs Cutting-edge Eye Surgeries 4Health News:Singapore Performs Cutting-edge Eye Surgeries 5
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: